Here are the Form 4 insider transactions from Cumberland Pharmaceuticals Inc (CPIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CPIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPIX filings page.
Cumberland Pharmaceuticals director Martin S. Brown Jr. received a grant of 1,800 shares of Common Stock at $2.80 per share. This award increased his direct holdings to 10,300 shares. The transaction is coded as a grant or award acquisition, indicating compensation rather than an open-market purchase.
Galante Joseph C reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals director Joseph C. Galante received a grant of 1,800 shares of Common Stock at $2.80 per share. This award increases his directly held stake to 63,656 shares. The transaction is classified as a grant or award, not an open-market purchase.
Jones James reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals director James Jones received a stock grant as part of his compensation. He was awarded 1,800 shares of Common Stock at a value of $2.80 per share. Following this grant, he directly owns 46,863 shares, indicating a routine, compensation-related increase in his holdings.
Cumberland Pharmaceuticals director Kenneth Krogulski received stock awards totaling 5,800 shares of common stock. The grants were recorded at a price of $2.80 per share on March 18, 2026. Following these award acquisitions, he directly holds 302,338 shares of Cumberland Pharmaceuticals common stock.
Cumberland Pharmaceuticals director Caroline Young received a grant of 1,800 shares of Common Stock of CUMBERLAND PHARMACEUTICALS INC. The shares were awarded at a price of $2.80 per share. Following this compensation-related acquisition, she directly holds 35,109 shares of the company’s common stock.
Cumberland Pharmaceuticals vice president receives new stock options grant. Vice President of Organizational Development Anthony Todd M. was granted options to acquire 3,000 shares of Cumberland Pharmaceuticals common stock at an exercise price of $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 18, 2036. Following this award, his reported derivative holdings total 21,000 options.
Bitterman Chris T. reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals vice president of sales and marketing Chris T. Bitterman received a grant of options to buy 3,000 shares of common stock at $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 16, 2036. Following this award, he holds options covering 19,000 shares in total.
Cumberland Pharmaceuticals Vice President and Chief Financial Officer John M. Hamm received a grant of 3,000 stock options on March 18, 2026. These options carry an exercise price of $2.80 per share and expire on March 18, 2036, bringing his reported option holdings to 18,250 shares.
Cumberland Pharmaceuticals executive James L. Herman received a grant of 2,500 stock options linked to the company’s common stock. The options carry an exercise price of 2.80 per share, become exercisable on 2030-03-18, and expire on 2036-03-18.
After this award, Herman holds a total of 21,000 options directly. This is a routine compensation-related grant rather than an open-market purchase or sale, so it does not reflect new trading activity in the company’s stock.
Cumberland Pharmaceuticals Chairman and CEO A. J. Kazimi received a grant of stock options covering 100,000 shares of common stock at an exercise price of $2.8000 per share. After this award, he holds options for a total of 568,000 shares, reflecting compensation rather than an open-market purchase.
Cumberland Pharmaceuticals chairman and CEO A.J. Kazimi reported a tax-related share disposition. On this Form 4, 5,845 shares of Common Stock were withheld at $3.06 per share to cover tax obligations. After this non-market transaction, he directly holds 5,695,310 shares of Cumberland Pharmaceuticals.
Cumberland Pharmaceuticals director Caroline Young reported a series of small open‑market purchases of the company’s common stock in December 2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows daily acquisitions ranging from $2.24 to $4.32 per share between 12/01/2025 and 12/31/2025, each coded as transaction type “L.”
After the final reported purchase on 12/31/2025 at $3.91 per share, Young beneficially owned 33,309 shares of Cumberland common stock in direct form. A footnote explains that the purchases occurred automatically under a Rule 10b5-1 plan adopted on November 14, 2024, indicating these trades were scheduled in advance.
Cumberland Pharmaceuticals director Kenneth J. Krogulski reported a series of small open-market purchases of the company’s common stock in December 2025. The transactions, coded “L,” were executed under a Rule 10b5-1 trading plan that he adopted on November 14, 2024. Individual daily purchases ranged from dozens of shares at prices in the low single digits per share. The most recent reported transaction was on December 31, 2025, when he bought 62 shares at $3.91 each, bringing his directly held stake to 296,538 common shares following that trade.
Cumberland Pharmaceuticals (CPIX) — insider share acquisitions reported. Director Caroline Young disclosed a series of automatic purchases executed under a Rule 10b5-1 trading plan.
The filing lists acquisitions of 6 shares on multiple trading days from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following the final reported transaction on October 31, 2025, the director beneficially owned 33,168 shares, held directly. The transactions were made pursuant to a 10b5-1 plan adopted on November 14, 2024.
Cumberland Pharmaceuticals (CPIX) director James Jones reported automatic open‑market purchases under a Rule 10b5‑1 trading plan. The filings show purchases of 13 shares on each trading day from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following these transactions, Jones beneficially owns 44,491 shares, held direct.
The Rule 10b5‑1 plan was adopted on November 14, 2024. No derivative securities were reported.
Cumberland Pharmaceuticals (CPIX) reported insider acquisitions by Chairman & CEO A.J. Kazimi on a Form 4. The filing lists a series of 13-share purchases on multiple days from 10/01/2025 through 10/31/2025, executed under a Rule 10b5-1 trading plan.
Reported prices ranged from $3.14 to $3.63 per share across the period. Following the latest transaction, Kazimi’s direct beneficial ownership is 5,700,583 shares.
Cumberland Pharmaceuticals (CPIX) director reported a series of open‑market purchases executed automatically under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred on multiple trading days from October 1 to October 31, 2025, with 68 shares acquired each day at prices generally in the $3.14–$3.63 range.
Following these purchases, the reporting person’s directly held stake was 292,595 shares as of October 31, 2025. The filing indicates it was made by a single reporting person serving as a Director, with all holdings shown as Direct (D).
Caroline Young, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a sequence of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. Purchases occurred on multiple dates from 09/02/2025 through 09/30/2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported trade on 09/30/2025, the filing shows 33,030 shares beneficially owned by Ms. Young.
The transactions were automatic under the disclosed 10b5-1 plan; the filing is signed by an attorney-in-fact on behalf of Ms. Young and contains no derivative transactions or other compensatory awards. All information is limited to the trades listed and the plan adoption date disclosed in the explanation section.
James Jones, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a series of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred daily from September 2, 2025 through September 30, 2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported purchase on September 30, 2025, the filing shows 44,192 shares beneficially owned by the reporting person. All transactions are reported as acquisitions and are marked as direct ownership.
A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of open-market purchases executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported transactions occurred between September 2, 2025 and September 30, 2025, with incremental buys at prices ranging from $3.05 to $3.60. Following the transactions, the filing shows beneficial ownership of 5,700,284 shares. The Form 4 was signed by an attorney-in-fact, John Hamm, on October 3, 2025. The filing identifies the reporting person as a Director, 10% owner, and Chairman and CEO.
Kenneth J. Krogulski, a director of Cumberland Pharmaceuticals Inc. (CPIX), reported a sequence of open-market purchases of the issuer's common stock executed between 09/02/2025 and 09/30/2025. The transactions were completed under a pre-established Rule 10b5-1 trading plan adopted on 11/14/2024 and were executed automatically.
Across multiple dates Mr. Krogulski acquired shares at prices ranging from $3.05 to $3.60, resulting in beneficial ownership of 291,031 shares following the reported transactions. Each purchase is reported as a direct ownership change and the purchases are shown as individual trades on consecutive trading days in September 2025.
Caroline Young, a director of Cumberland Pharmaceuticals Inc. (CPIX), purchased shares of the company in multiple automatic trades executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported purchases occurred across trading dates from July 1 through July 31, 2025, at per-share prices ranging about $3.05 to $3.82. Following the reported transactions, her beneficial ownership increased from 32,661 shares to 32,821 shares, a net gain of 160 shares.
The filing confirms the trades were made pursuant to the pre-established 10b5-1 plan and signed by an attorney-in-fact on behalf of the reporting person. No sales, derivative transactions, or other changes in relationship to the issuer are reported in this Form 4.
James Jones, identified as a director of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of systematic purchases of the issuer's common stock during July 2025. The table discloses multiple acquisitions executed across July 1–31, 2025, with reported transaction prices ranging from $3.05 to $3.82 per share. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
The Form shows the reporting person’s beneficial ownership rising through the month, culminating at 43,676 shares following the July 31, 2025 purchase. The filing was signed by an attorney-in-fact on behalf of James Jones and discloses the transactions as purchases under the Section 16 reporting requirements.
A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals (CPIX), reported a series of purchases of the company's common stock executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. Transactions recorded in the Form 4 run from July 1 through July 31, 2025 at prices shown in the filing ranging from $3.05 to $3.82.
All reported shares are held directly. After the reported transactions, the Form 4 shows beneficial ownership of 5,699,768 shares. The filing identifies the reporting person as a Director, Chairman and CEO and a 10% owner, and notes the purchases occurred automatically pursuant to the 10b5-1 plan.
Kenneth J. Krogulski, a director of Cumberland Pharmaceuticals Inc. (CPIX), executed a series of automated purchases of the company's common stock during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. Over 22 trading dates from July 1 to July 31, the reporting shows purchases totaling 1,712 shares, increasing his direct beneficial ownership to 288,345 shares. Transaction prices ranged from $3.05 to $3.82, with individual daily purchases of mostly 80 shares and later 68 shares.
The Form 4 indicates these purchases were made automatically pursuant to the previously adopted 10b5-1 plan and that ownership is held directly. No derivative transactions or other classes of securities are reported on this filing.
SEC Form 4 filing dated 07/11/2025 reports a series of open-market purchases of Cumberland Pharmaceuticals Inc. (CPIX) common stock by director Caroline Young.
Transaction details:
- 20 separate buy transactions executed from 06/02/2025 to 06/30/2025.
- Total shares acquired: 84 (nineteen lots of 4 shares and one lot of 8 shares).
- Price range: $2.60 – $6.00 per share.
- Weighted-average purchase price: approximately $4.81 per share (derived from disclosed price and share data).
- Total cost: about $403.60.
All trades were automatically executed under a Rule 10b5-1 trading plan adopted on 11/14/2024, as noted in the Explanation of Responses.
Following the reported transactions Ms. Young’s direct beneficial ownership stands at 32,653 CPIX shares. No derivative security activity was reported, and the filing indicates that Ms. Young continues to serve as a director of the company.
The filing does not provide information on company operations, earnings or additional insider activity. The share-price pattern shows a steady decline over the month—from $5.20 on 06/02 to $2.74 on 06/30—suggesting the purchases occurred during a period of price weakness.
Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 filing, 11 Jul 2025
Chairman, CEO and 10% owner A. J. Kazimi reported a series of open-market purchases carried out automatically under a Rule 10b5-1 trading plan adopted on 14 Nov 2024. Between 02 Jun 2025 and 30 Jun 2025 he bought about 160 common shares in 20 small daily lots (mostly 8 shares, last lot 16 shares). Purchase prices ranged from $6.00 at the start of the period to $2.60 at month-end, implying an average cost close to $5.0 per share (≈ $800 total).
Kazimi’s direct beneficial ownership increased from 5,699,268 to 5,699,428 shares. No derivative securities were involved. Because the transactions represent <0.003% of his existing stake and were pre-scheduled, the filing is largely administrative, although consistent insider buying—despite the share-price decline—can be viewed as a minor vote of confidence.
Form 4 filing for Cumberland Pharmaceuticals Inc. (CPIX) details a series of open-market purchases executed by director Kenneth J. Krogulski under an existing Rule 10b5-1 trading plan adopted on 14 Nov 2024.
- Transaction window: 2 Jun 2025 – 30 Jun 2025 (20 trading days).
- Shares acquired: 935 common shares (19 trades of 45 shares each and one trade of 80 shares).
- Total cost basis: purchase prices ranged from $2.60 – $6.00 per share, indicating declining market prices over the period.
- Ownership change: holdings rose from 285,743 to 286,633 shares, a 0.3% increase.
- Transaction code “P” confirms open-market purchases; the “V” footnote references execution under the 10b5-1 plan.
No derivative securities were reported, and there were no dispositions. The filing is routine in nature and does not announce any corporate events, earnings data, or material changes beyond the incremental insider accumulation.